Sweden
· Delayed Price · Currency is SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of SEK 475.56 million. The enterprise value is 207.17 million.
| Market Cap | 475.56M |
| Enterprise Value | 207.17M |
Important Dates
The next estimated earnings date is Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncopeptides AB has 215.19 million shares outstanding. The number of shares has increased by 3.27% in one year.
| Shares Outstanding | 215.19M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 21.96% |
| Float | 179.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.25 |
| PB Ratio | 2.46 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.79 |
| EV / Sales | 9.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.21 |
Financial Position
The company has a current ratio of 3.48, with a Debt / Equity ratio of 59.54.
| Current Ratio | 3.48 |
| Quick Ratio | 3.44 |
| Debt / Equity | 59.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.67 |
| Interest Coverage | -32.70 |
Financial Efficiency
Return on equity (ROE) is -141.97% and return on invested capital (ROIC) is -53.97%.
| Return on Equity (ROE) | -141.97% |
| Return on Assets (ROA) | -39.64% |
| Return on Capital (ROIC) | -53.97% |
| Revenue Per Employee | 318,940 |
| Profits Per Employee | -3.92M |
| Employee Count | 57 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.04 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.66% in the last 52 weeks. The beta is -0.35, so Oncopeptides AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.35 |
| 52-Week Price Change | -57.66% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 3.89 |
| Relative Strength Index (RSI) | 41.97 |
| Average Volume (20 Days) | 662,990 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of SEK 21.37 million and -262.70 million in losses. Loss per share was -1.22.
| Revenue | 21.37M |
| Gross Profit | 21.25M |
| Operating Income | -256.53M |
| Pretax Income | -260.53M |
| Net Income | -262.70M |
| EBITDA | -253.88M |
| EBIT | -256.53M |
| Loss Per Share | -1.22 |
Balance Sheet
The company has 383.28 million in cash and 114.89 million in debt, giving a net cash position of 268.39 million or 1.25 per share.
| Cash & Cash Equivalents | 383.28M |
| Total Debt | 114.89M |
| Net Cash | 268.39M |
| Net Cash Per Share | 1.25 |
| Equity (Book Value) | 192.96M |
| Book Value Per Share | 0.90 |
| Working Capital | 299.60M |
Cash Flow
In the last 12 months, operating cash flow was -171.78 million and capital expenditures -116,000, giving a free cash flow of -171.89 million.
| Operating Cash Flow | -171.78M |
| Capital Expenditures | -116,000 |
| Free Cash Flow | -171.89M |
| FCF Per Share | -0.80 |
Margins
| Gross Margin | 99.44% |
| Operating Margin | -1,200.48% |
| Pretax Margin | -1,219.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -804.39% |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | -3.27% |
| Earnings Yield | -55.24% |
| FCF Yield | -36.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |